Phase I Dose-Escalation Parallel Studies of Intraperitoneal Oxaliplatin With Intravenous Docetaxel and Intravenous Oxaliplatin With Intraperitoneal Docetaxel in Platinum-Sensitive or Platinum-Resistant Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer.

Trial Profile

Phase I Dose-Escalation Parallel Studies of Intraperitoneal Oxaliplatin With Intravenous Docetaxel and Intravenous Oxaliplatin With Intraperitoneal Docetaxel in Platinum-Sensitive or Platinum-Resistant Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Docetaxel (Primary) ; Docetaxel (Primary) ; Oxaliplatin (Primary) ; Oxaliplatin (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Mar 2013 Planned end date changed from 1 Dec 2011 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 15 Jan 2010 Planned end date changed from 1 Dec 2009 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 01 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top